EyeGene Inc (185490) — Cash Flow-to-Debt Ratio
EyeGene Inc (185490) has a Cash Flow-to-Debt Ratio of -0.23x as of March 2026, meaning its operating cash flow of ₩-3.13 Billion could theoretically repay 0% of its total liabilities (₩13.78 Billion) in one year. Explore 185490 long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
EyeGene Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for EyeGene Inc across 12 annual periods. Also explore EyeGene Inc balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for EyeGene Inc (2014–2025)
Year-by-year debt coverage analysis for EyeGene Inc. For market capitalisation and broader financial context, see EyeGene Inc (185490) total market value.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.43x | ₩-5.98 Billion | ₩13.80 Billion | ▲ +46.6% |
| 2024 | -0.81x | ₩-12.17 Billion | ₩14.98 Billion | ▲ +44.3% |
| 2023 | -1.46x | ₩-20.07 Billion | ₩13.77 Billion | ▼ -7.2% |
| 2022 | -1.36x | ₩-18.57 Billion | ₩13.65 Billion | ▲ +27.4% |
| 2021 | -1.87x | ₩-30.00 Billion | ₩16.02 Billion | ▼ -505.3% |
| 2020 | -0.31x | ₩-9.75 Billion | ₩31.53 Billion | ▼ -5.1% |
| 2019 | -0.29x | ₩-8.32 Billion | ₩28.28 Billion | ▼ -20.7% |
| 2018 | -0.24x | ₩-7.48 Billion | ₩30.70 Billion | ▲ +76.5% |
| 2017 | -1.03x | ₩-6.76 Billion | ₩6.53 Billion | ▲ +59.0% |
| 2016 | -2.52x | ₩-5.99 Billion | ₩2.37 Billion | ▲ +11.8% |
| 2015 | -2.86x | ₩-4.48 Billion | ₩1.57 Billion | ▼ -102.1% |
| 2014 | -1.42x | ₩-2.39 Billion | ₩1.69 Billion | — |